Biotech | February 24, 2022
Aadi Bioscience launches Fyarro in the USA
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Darolutamide is developed jointly by Bayer and Orion Corporation
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Subscribe To Our Newsletter & Stay Updated
